FAQ: Dr. Judith Hochman's 2025 Research Achievement Award and Her Impact on Cardiology

Who is receiving the 2025 Research Achievement Award and why?

Dr. Judith S. Hochman, senior associate dean for clinical sciences and founding director of the Cardiovascular Clinical Research Center at NYU Grossman School of Medicine, is receiving the award for her distinguished career and research that has directly influenced global clinical practice guidelines in cardiology.

When and where will Dr. Hochman receive this award?

She will be presented with the award during the opening session on Sunday, November 9, 2025, at the American Heart Association’s Scientific Sessions 2025 in New Orleans.

What are Dr. Hochman’s key roles and positions?

She serves as senior associate dean for clinical sciences, founding director of the Cardiovascular Clinical Research Center at NYU Grossman School of Medicine, founding co-director of NYU Langone Health’s Clinical and Translational Science Institute, and Harold Snyder Family Professor of Cardiology.

What were Dr. Hochman’s most impactful clinical trials?

She was principal investigator for three landmark trials: the Occluded Artery Trial (OAT), the SHOCK Trial, and the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA Trial).

What were the key findings from Dr. Hochman’s SHOCK Trial?

The SHOCK Trial established that emergency revascularization in patients with cardiogenic shock due to left ventricular failure after acute MI reduced mortality rates by 13 absolute percentage points at one-year and long-term, leading to increased use of early revascularization with improved survival.

What did the ISCHEMIA trial discover about treatment for stable coronary artery disease?

The ISCHEMIA trial found no significant difference in all-cause mortality between invasive versus conservative treatment strategies, but identified substantial quality-of-life improvement among patients with angina who received invasive treatment.

How have Dr. Hochman’s trials influenced clinical practice?

Her three major trials led to new and revised recommendations regarding the role of revascularization in joint clinical guidelines from the American Heart Association and other organizations, directly impacting patient care globally.

Who is presenting the award to Dr. Hochman and what did they say about her work?

Dr. Stacey E. Rosen, the American Heart Association’s 2025-2026 volunteer president, will present the award, stating that Dr. Hochman’s research has directly impacted patient care across the full spectrum of ischemic heart disease and calling her a visionary leader unafraid to tackle complex questions.

What is the significance of the American Heart Association’s Scientific Sessions?

It is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science, held November 7-10, 2025, in New Orleans.